ArticleFrontiers in medicine2023
Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus.
John PuetzPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it